Skip to main content

Table 2 Serum biochemistry data and HDL composition of patients with prostate cancer before and after androgen deprivation therapy (n = 16)

From: Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma

 

Basal

Post-treatment

P-value

Glycemia (mg/dL)

103 ± 16

102 ± 17

0.909

Cholesterol (mg/dL)

 total

194 ± 47

209 ± 37

0.112

 LDL

119 ± 43

133 ± 30

0.194

 HDL

48 ± 11

51 ± 15

0.191

 non-HDL

146 ± 46

158 ± 34

0.159

 unesterified

48 ± 12

56 ± 12

0.019

Triglycerides

111 ± 54

127 ± 55

0.079

LCAT (μg/mL)

7.15 ± 1.81

8.01 ± 1.55

0.020

CETP (μg/mL)

2.47 ± 0.78

2.48 ± 0.77

0.999

HDL lipid composition (%)

 Esterified cholesterol

43.2 ± 8.8

43.5 ± 11.0

0.880

 Unesterified cholesterol

6.4 ± 2.5

6.9 ± 2.4

0.352

 Triglycerides

9.5 ± 3.2

9.6 ± 3.0

0.923

 Phospholipids

49.8 ± 25.1

39.1 ± 26.6

0.073

  1. LDL Low density lipoprotein, HDL High density lipoprotein, LCAT lecithin cholesterol acyl transferase, CETP Cholesteryl ester transfer protein